COMPARATIVE EFFICACY OF INTRACAMERAL 0.5% MOXIFLOXACIN VERSUS 0.1% CEFUROXIME IN PREVENTING POSTOPERATIVE ENDOPHTHALMITIS FOLLOWING PHACOEMULSIFICATION CATARACT SURGERY: A RANDOMIZED CONTROLLED TRIAL
DOI:
https://doi.org/10.71000/357k3a15Keywords:
Anti-Bacterial Agents; Cataract Extraction; Cefuroxime; Endophthalmitis; Moxifloxacin; Phacoemulsification; Postoperative Complications.Abstract
Background: Postoperative endophthalmitis is an uncommon but vision-threatening complication of cataract surgery that can result in serious ocular morbidity if not prevented or treated promptly. Intracameral antibiotic prophylaxis has become an important preventive strategy in modern phacoemulsification surgery. Cefuroxime and moxifloxacin are commonly used agents, but comparative local evidence remains limited. This study was conducted to compare their prophylactic efficacy in preventing postoperative endophthalmitis after cataract surgery.
Objective: To compare the efficacy of intracameral 0.5% moxifloxacin and intracameral 0.1% cefuroxime in preventing postoperative endophthalmitis following phacoemulsification cataract surgery.
Methods: This randomized controlled trial was conducted at the Institute of Ophthalmology, Mayo Hospital, Lahore, over six months from 27 June 2022 to 27 December 2022. A total of 60 patients aged 50–70 years undergoing phacoemulsification cataract surgery were enrolled through non-probability consecutive sampling and randomly allocated into two equal groups by lottery method. Group A received intracameral cefuroxime 1 mg in 0.1 mL saline, while Group B received intracameral moxifloxacin 100 µg in 0.1 mL saline at the end of surgery. Patients were followed for six weeks postoperatively to assess prophylactic efficacy. Data were analyzed using SPSS version 25, with p≤0.05 considered statistically significant.
Results: The mean age was 60.13 ± 5.84 years in the cefuroxime group and 59.56 ± 5.41 years in the moxifloxacin group. Mean disease duration was 2.33 ± 0.80 weeks and 2.36 ± 0.72 weeks, respectively, with no significant difference (p=0.866). In the cefuroxime group, 11 patients were male and 19 were female, while in the moxifloxacin group, 16 were male and 14 were female (p=0.299). Efficacy was achieved in 20 patients in the cefuroxime group and 28 patients in the moxifloxacin group, showing a statistically significant difference (p=0.021).
Conclusion: Intracameral moxifloxacin demonstrated higher prophylactic efficacy than intracameral cefuroxime in preventing postoperative endophthalmitis after phacoemulsification cataract surgery. These findings support its potential use as an effective intracameral antibiotic option in routine cataract surgery.
Keywords: Anti-Bacterial Agents; Cataract Extraction; Cefuroxime; Endophthalmitis; Moxifloxacin; Phacoemulsification; Postoperative Complications.
References
Shao EH, Yates WB, Ho I, Chang AA, Simunovic MP. Endophthalmitis: changes in presentation, management and the role of early vitrectomy. Ophthalmol Ther. 2021;10(4):877-90.
Wang XL, Huang XY, Wang Z, Sun W. The Anterior Chamber Injection of Moxifloxacin Injection to Prevent Endophthalmitis after Cataract Surgery: A Meta- analysis. Journal of Ophthalmology. 2020 Aug 25;2020.
Rathi VM, Sharma S, Das T, Khanna RC. Endophthalmitis prophylaxis study. Report, intracameral cefuroxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India. Indian J Ophthalmol. 2020;68:819-24.
Melega MV, Alves M, Lira RP, da Silva IC, Ferreira BG, Assis Filho HL, et al. Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: randomized controlled clinical trial. J Cataract Refract Surg. 2019;45(3):343-50.
Llovet-Rausell A, Llovet-Osuna F, Ortega-Usobiaga J, Beltran-Sanz J, Druchkiv V. Acute postoperative endophthalmitis after phacoemulsification in a private ophthalmic surgical group. Arch Soc Esp Oftalmol (Engl Ed). 2025;100(3):125-33.
Grzybowski A, Brona P, Zeman L, Stewart MW. Commonly used intracameral antibiotics for endophthalmitis prophylaxis: A literature review. Surv Ophthalmol. 2021;66(1):98-108.
Anwar F, Qamar N, Bashir A, Ghaffar MT, Bokhari MH. EFFICACY OF INTRACAMERAL MOXIFLOXACIN VERSUS TOPICAL MOXIFLOXACIN IN PREVENTING ACUTE ENDOPHTHALMITIS AFTER CATARACT SURGERY BY PHACOEMULSIFICATION. J Ayub Med Coll Abbottabad. 2024;36(2):256-9.
Salha CP, Machado LN, Santos MSD. Efficacy of prophylactic intracameral antibiotic in preventing endophthalmitis after cataract surgery. Arq Bras Oftalmol. 2024;88(3).
Friling E, Bro T, Lundström M, Montan P. Endophthalmitis after cataract surgery and effect of different intracameral antibiotic regimes in Sweden 2011-2017: national registry study. J Cataract Refract Surg. 2024;50(8):828-35.
Peck TJ, Patel SN, Ho AC. Endophthalmitis after cataract surgery: an update on recent advances. Curr Opin Ophthalmol. 2021;32(1):62-8.
Shorstein NH, Liu L, Carolan JA, Herrinton L. Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery. Am J Ophthalmol. 2021;227:166-72.
Chang DF. The ESCRS intracameral cefuroxime study: the debate continues. J Cataract Refract Surg. 2021;47(2):150-2.
Olson RJ. The ESCRS postoperative endophthalmitis prospective trial 15 years later. J Cataract Refract Surg. 2021;47(7):839-41.
Lieu AC, Jun JH, Afshari NA. Intracameral antibiotics during cataract surgery: efficacy, safety, and cost-benefit considerations. Curr Opin Ophthalmol. 2024;35(1):50-6.
Agarwal A, Nagpal M. Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety. Indian J Ophthalmol. 2021;69(2):326-30.
Sen S, Mishra C, Rameshkumar G, Babu Kannan N, Shekhar M, Lalitha P. Microbiological Profile of Post-cataract Surgery Endophthalmitis with Usage of Prophylactic Intracameral Moxifloxacin. Ocul Immunol Inflamm. 2024;32(6):796-802.
Filipe HP, Bozukova D, Pimenta A, Vieira AP, Oliveira AS, Galante R, et al. Moxifloxacin-loaded acrylic intraocular lenses: In vitro and in vivo performance. J Cataract Refract Surg. 2019;45(12):1808-17.
Mamalis N. Reducing the risk of endophthalmitis. J Cataract Refract Surg. 2019;45(9):1217-8.
Galvis V, Prada AM, Tello A, Parra MM, Camacho PA, Polit MP. Safety of intracameral application of moxifloxacin and dexamethasone (Vigadexa®) after phacoemulsification surgery. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3215-21.
Chen KJ, Chong YJ, Sun MH, Chen HC, Liu L, Chen YP, et al. Streptococcus pneumoniae endophthalmitis: clinical settings, antibiotic susceptibility, and visual outcomes. Sci Rep. 2021;11(1):6195.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dr Saima Khalid, Dr Bahadur Iftikhar, Dr. Muhammad Qasim Yazar, Dr. Wazir Muhammad Hasan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
